STAT+: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

A House lawmaker asked the Government Accountability Office to review whether the TrumpRx platform has saved Americans any money.

In an Oct. 27 letter, Frank Pallone (D-N.J.), the ranking member of the House Committee on Energy and Commerce, said the White House has made “sweeping statements” that the website has helped Americans save $700 million since it was launched in February. TrumpRx does not sell or dispense drugs but directs consumers to coupons or links for discounts.

However, Pallone said the Trump administration has failed to “disclose key information” that would help evaluate whether the platform has provided “any meaningful financial benefit,” he wrote. In particular, he cited the lack of details about most-favored nation agreements the White House reached with more than two dozen drugmakers.